Corticosteroid therapy for sarcoidosis

Sarcoidosis

Volumn , Issue , 2005, Pages 689-716

  White, Eric S ^a   Keena, Daniel T ^a   Zisman, David A ^b   Lynch, Joseph P ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85051689227     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (168)

1. Johns CJ, Michele TM. The clinical management of sarcoidosi. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 1999; 78(2): 65-111.
2. Fazzi P. Pharmacotherapeutic management of pulmonary sarcoidosis. Am J Respir Med 2003; 2(4): 311-320.
3. Sharma OP. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis 1993; 147(6 Pt 1): 1598-1600.
4. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997; 111(3): 623-631.
5. Lynch JP III, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med 1997; 18(4): 755-785.
6. Lynch J III, Baughman R, Sharma O. Extrapulmonary sarcoidosis. Semin Respir Infect 1998; 13: 229-254.
7. Baughman RP, Sharma OP, Lynch JP III. Sarcoidosis: is therapy effective? Semin Respir Infect 1998; 13(3): 255-273.
8. Siltzbach LE, James DG, Neville E, Turiaf J, Battesti JP, Sharma OP, Hosoda Y, Mikami R, Odaka M. Course and prognosis of sarcoidosis around theworld. Am J Med 1974; 57(6): 847-852.
9. Romer FK. Presentation of sarcoidosis and outcome of pulmonary changes. Dan Med Bull 1982; 29(1): 27-32.
10. Hillerdal G, Nou E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosi. A 15-year European study. Am Rev Respir Dis 1984; 130(1): 29-32.
11. Neville E, Walker A, James DG. Prognostic factors predicting the outcome of sarcoidosis: An analysis of 818 patients. Q J Med 1983; 208: 525-533.
12. Lynch JP III. Pulmonary sarcoidosis: current concepts & controversies. Compr Ther 1997; 23(3): 197-210.
13. Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data. Am J Med 1996; 100(4): 423-427.
14. Reich JM, Johnson RE. Course and prognosis of sarcoidosis in a nonreferral setting. Analysis of 86 patients observed for 10 years. Am JMed 1985; 78(1): 61-67.
15. Reich JM. Mortality of intrathoracic sarcoidosis in referral vs populationbased settings: influence of stage, ethnicity, and corticosteroid therapy. Chest 2002; 121(1): 32-39.
16. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995; 119(2): 167-172.
17. Lynch JP III, Baughman RP. When and how to use steroids for sarcoidosis. J Respir Dis 1998; 19(2): 122-132.
18. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160(2): 736-755.
19. Costabel U. Sarcoidosis: clinicalupdate. Eur Respir J 2001; 18(suppl32): 56s-68s.
20. Westall GP, Stirling RG, Cullinan P, du Bois RM. Sarcoidosis. In: Schwarz MI, King TE, eds. Interstitial Lung Disease. 4th ed. Hamilton: BC Decker, 2003: 332-386.
21. Ellis EF. Adverse effects of corticosteroid therapy. J Allergy Clin Immunol 1987; 80(4): 515-517.
22. Streeten DH. Corticosteroid therapy: pharmacology, indications, and adverse effects. Compr Ther 1976; 2(2): 59-63.
23. Kershner P, Wang-Cheng R. Psychiatric side effects of steroid therapy. Psychosomatics 1989; 30(2): 135-139.
24. White ES, Lynch JP III. Sarcoidosis involving multiple systems: diagnostic and therapeutic challenges. Chest 2001; 119(5): 1593-1597.
25. Sharma OP. Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest 1997; 112(1): 220-228.
26. Eule H, Weinecke A, Roth I, Wuthe H. The possible influence of corticosteroid therapy on the natural course of pulmonary sarcoidosis. Late results of a continuing clinical study. Ann N Y Acad Sci 1986; 465: 695-701.
27. Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 1973; 107(4): 609-614.
28. Yamamoto M, Saito N, Tachibana T. Effects of an 18month corticosteroid therapy to stage I and stage II sarcoidosis patients (control trial). In: Chretien J, Marsac J, Saltiel JC, eds. Sarcoidosis and Other Granulomatous Disorders. Paris: Pergamon Press, 1980: 470-474.
29. Zaki M, Lyons H, Leilop L, Huang C. Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study. N Y State J Med 1987; 87: 496-499.
30. Freiman DG. Sarcoidosis. N Engl J Med 1948; 239: 709-716.
31. Curtis AC, Taylor H, Grekin RH. Sarcoidosis. I. Results of treatment with varying amounts of calciferol and dihydrotachysterol. J Invest Dermatol 1947; 9: 131-150.
32. Snider GE. Treatment of Boeck’s sarcoid with nitrogen mustard: preliminary report. South Med J 1948; 41: 11-14.
33. Jones R. Use of urethane in treatment of sarcoidosis: preliminary report. In: Eastern Pennsylvania regional meeting of the American College of Physicians, 1950, Philadelphia, 1950.
34. Thorn GW, Forsham PH, Frawley TF, Hill SR Jr, Roche M, Staehelin D, Wilson DL. Clinical usefulness of ACTH and cortisone. N Engl J Med 1950; 242: 783-793, 824-834, 65-72.
35. Olson JA, Steffenson EH, Margulis RR, Smith RW, Whitney RL. Effect of ACTH on certain inflammatory diseases of eye: preliminary report. JAMA 1950; 142: 1276-1278.
36. Sones M, Israel HL, Dratman MB, Frank JH. Effect of cortisone in sarcoidosis. N Engl J Med 1951; 244: 209-213.
37. Siltzbach LE. Effect of cortisone in sarcoidosis: a study of 13 patients. Am J Med 1952; 12: 139-160.
38. Israel HL, Sones M, Harrell D. Cortisone treatment of sarcoidosis: experience with thirty-six cases. JAMA 1954; 156(5): 461-466.
39. Sharma OP, Colp C, Williams MH. Course of pulmonary sarcoidosis with and without corticosteroid therapy as determined by pulmonary function studies. Am J Med 1966; 41: 541-551.
40. Stone DJ, Schwartz A. A long-term study of sarcoid and its modification by steroid therapy. Lung function and other factors in prognosis. Am J Med 1966; 41(4): 528-540.
41. Hoyle C, Smyllie H, Leak D. Prolonged treatment of pulmonary sarcoidosis with corticosteroids. Thorax 1967; 22: 519-524.
42. Emirgil C, Sobol BJ, Williams MH Jr. Long-term study of pulmonary sarcoidosis. The effect of steroid therapy as evaluated by pulmonary function studies. J Chronic Dis 1969; 22(2): 69-86.
43. Stone DJ, Schwartz A, Feltman JA, Lovelock FJ. Pulmonary function in sarcoidosis and results with cortisone therapy. Am J Med 1953; 15: 468.
44. McClement JH, Renzetti AD, Himmelstein A, Cournand A. Cardiopulmonary function in the pulmonary form of Boeck’s sarcoid and its modification by cortisone therapy. Am Rev Tuberc 1953; 67: 154.
45. Rudberg-Roos I, Roos BE. Pulmonary function in sarcoidosis before and after ACTH and cortisone therapy. Acta Tuberc Scand 1958; 35: 49.
46. Scadding J. Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years’ observation. Br Med J 1961; 2: 1165-1172.
47. Sones M, Israel HL. Course and prognosis of sarcoidosis: Philadelphia. Am Rev Respir Dis 1961; 84(5 Pt 2): 60-65.
48. James DG. Course and prognosis of sarcoidosis: London. Am Rev Respir Dis 1961; 84(5 Pt 2): 66-70.
49. Lofgren S, Stavenow S. Course and prognosis of sarcoidosis: Stockholm. Am Rev Respir Dis 1961; 84(5 Pt 2): 71-73.
50. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002; 287(10): 1301-1307.
51. Rossi GA, Di Negro GB, Balzano E, Cerri E, Sacco O, Balbi B, Venturini A, Ramoino R, Ravazzoni C. Suppression of the alveolitis in pulmonary sarcoidosis by oral corticosteroids. Lung 1985; 163: 83-93.
52. Johns CJ, Schonfeld SA, Scott PP, Zachary JB, MacGregor MI. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. Ann N YAcad Sci 1986; 465: 702-712.
53. DeRemee J. The present status of treatment of pulmonary sarcoidosis: a house divided. Chest 1977; 71: 388-393.
54. Johns CJ, Macgregor MI, Zachary JB, Ball WC. Extended experience in the long-term corticosteroid treatment of pulmonary sarcoidosis. Ann N YAcad Sci 1976; 278: 722-731.
55. Judson MA, Baughman RP, Thompson BW, Teirstein AS, Terrin ML, Rossman MD, Yeager H Jr, McLennan G, Bresnitz EA, DePalo L, et al. ACCESS Research Group. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diff Lung Dis 2003; 20(3): 204-211.
56. Izumi T. Are corticosteroids harmful to sarcoidosis? Sarcoidosis 1994; 11: 119-122.
57. Hunninghake GW, Gilbert S, Pueringer R, Dayton C, Floerchinger C, Helmers R, Merchant R, Wilson J, Galvin J, Schwartz D. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994; 149(4 Pt 1): 893-898.
58. Takada K, Ina Y, Noda M, Sato T, Yamamoto M, Morishita M. The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis. J Clin Epidemiol 1993; 46(4): 359-366.
59. Sugisaki K, Yamaguchi T, Nagai S, Ohmiti M, Takenaka S, Morimoto S, Ishihara M, Tachibana T, Tsuda T. Clinical characteristics of 195 Japanese sarcoidosis patients treated with oral corticosteroids. Sarcoidosis Vasc Diff Lung Dis 2003; 20(3): 222-226.
60. James D, Carstairs L, Trowell J, Sharma O. Treatment of sarcoidosis: report of a controlled therapeutic trial. Lancet 1967; 2: 526-528.
61. Selroos O, Sellergren T. Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease. Scand J Respir Dis 1979; 60: 215-221.
62. Harkleroad LE, Young RL, Savage PJ, Jenkins DW, Lordon RE. Pulmonary sarcoidosis. Long-term follow-up of the effects of steroid therapy. Chest 1982; 82(1): 84-87.
63. Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK, Harrison BD. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51(3): 238-247.
64. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002; 121(1): 24-31.
65. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group. Chest 1999; 116(2): 424-431.
66. Wurm K, Reindell H, Heilmeyer L. Der Lungenboeck in Rontgenbild. Stuttgart, Germany: Thieme, 1958.
67. Siltzbach LE. Sarcoidosis: clinical features and management. Med Clin North Am 1967; 51(2): 483-502.
68. Glennas A, Kvien TK, Melby K, Refvem OK, Andrup O, Karstensen B, Thoen JE. Acute sarcoid arthritis: occurrence, seasonal onset, clinical features and outcome. Br J Rheumatol 1995; 34(1): 45-50.
69. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest 1993; 103(1): 253-258.
70. Winterbauer RH, Kirtland SH, Corley DE. Treatment with corticosteroids. Clin Chest Med 1997; 18(4): 843-851.
71. James DG, Sharma OP. Neurosarcoidosis. Proc R Soc Med 1967; 60(11 Pt 1): 1169-1170.
72. Block AJ, Light RW. Alternate day steroid therapy in diffuse pulmonary sarcoidosis. Chest 1973; 63(4): 495-504.
73. Spratling L, Tenholder F, Underwood G, Feaster L, Requa R. Daily versus alternate day predinose therapy for stage II sarcoidosis. Chest 1985; 88: 687-690.
74. Lynch JP III, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am JRespir Crit Care Med 1997; 155(2): 395-420.
75. Allen RK, Merory J. Intravenous pulse methyl prednisolone in the successful treatment of severe sarcoid polyneuropathy with pulmonary involvement. Aust N Z J Med 1985; 15(1): 45-46.
76. Spiteri MA, Newman SP, Clarke SW, Poulter LW. Inhaled corticosteroids can modulate the immunopathogenesis of pulmonary sarcoidosis. Eur Respir J 1989; 2(3): 218-224.
77. Spiteri MA. Inhaled corticosteroids in pulmonary sarcoidosis. Postgrad Med J 1991; 67(786): 327-329.
78. Erkkila S, Froseth B, Hellstrom PE, Kaltiokallio K, Taskinen E, Viljanen A, Viljanen B, Selroos O. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis 1988; 5(2): 106-110.
79. Selroos OB. Use of budesonide in the treatment of pulmonary sarcoidosis. Ann N Y Acad Sci 1986; 465: 713-721.
80. Alberts C, Jansen HM, Roos JM, Out TA. Effects of inhaled budesonide in patients with pulmonary sarcoidosis. Eur Respir J 1991; 4(suppl 14): 253.
81. Selroos OB. Biochemical markers in sarcoidosis. Crit Rev Clin Lab Sci 1986; 24(3): 185-216.
82. Milman N, Graudal N, Grode G, Munch E. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 1994; 236(3): 285-290.
83. Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J 1995; 8(5): 682-688.
84. Paramothayan NS, Jones PW. Corticosteroids for pulmonary sarcoidosis (Cochrane Review). Oxford: Update Software, 4.
85. Selroos O. Further experiences with inhaled budesonide in the treatment of pulmonary sarcoidosis. Amsterdam: Elsevier Science, 1988.
86. Zych D, Pawlicka L, Zielinski J. Inhaled budesonide versus prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1993; 10(1): 56-61.
87. Selroos O, Lofroos AB, Pietinalho A, Niemisto M, Riska H. Inhaled budesonide for maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1994; 11(2): 126-131.
88. du Bois RM, Greenhalgh PM, Southcott AM, Johnson NM, Harris TA. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 1999; 13(6): 1345-1350.
89. Baughman RP, Iannuzzi MC, Lower EE, Moller DR, Balkissoon RC, Winget DB, Judson MA. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diff Lung Dis 2002; 19(3): 198-204.
90. Khatri KA, Chotzen VA, Burrall BA. Lupus pernio: successful treatment with a potent topical corticosteroid. Arch Dermatol 1995; 131(5): 617-618.
91. Tami T. Sinonasal sarcoidosis: diagnosis and management. Semin Resp Crit Care Med 2002; 23: 549-654.
92. Krespi YP, Kuriloff DB, Aner M. Sarcoidosis of the sinonasal tract: a new staging system. Otolaryngol Head Neck Surg 1995; 112(2): 221-227.
93. Krespi YP, Mitrani M, Husain S, Meltzer CJ. Treatment of laryngeal sarcoidosis with intralesional steroid injection. Ann Otol Rhinol Laryngol 1987; 96(6): 713-715.
94. Obenauf CD, Shaw HE, Syndnor CF, Klintworth GK. Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol 1978; 86: 648-655.
95. James DG, Angi MR. Ocular sarcoidosis. In: James DG, ed. Sarcoidosis and Other Granulomatous Disorders. New York: Marcel Dekker, 1994: 275-284.
96. Bradley D, Baughman R, Raymond L, Kaufman A. Ocular manifestations of sarcoidosis. Semin Resp Crit Care Med 2002; 23: 543-548.
97. Mader TH, Chismire KJ, Cornell FM. The treatment of an enlarged sarcoid iris nodule with injectable corticosteroids. Am J Ophthalmol 1988; 106(3): 365-366.
98. Miglets AW, Barton CL. Sarcoid of the tonsil. Response to local steroid injection. Arch Otolaryngol 1970; 92(5): 516-517.
99. Judson MA, Uflacker R. Treatment of a solitary pulmonary sarcoidosis mass by CT-guided direct intralesional injection of corticosteroid. Chest 2001; 120(1): 316-317.
100. Deng J, Baughman R, Lynch JP III. Cardiac involvement in sarcoidosis. Semin Resp Crit Care Med 2002; 23: 513-528.
101. Fleming HA. Sarcoid heart disease. Br Heart J 1974; 36(1): 54-68.
102. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, De Palo L, Hunninghake G, Iannuzzi MC, Johns CJ, et al. Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164(10 Pt 1): 1885-1889.
103. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the hea. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 1977; 63(1): 86-108.
104. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978; 58(6): 1204-1211.
105. Fleming H. Cardiac sarcoidosis. In: James DG, ed. Sarcoidosis and Other Granulomatous Disorders. New York: Marcel Dekker, 1994: 323-334.
106. Shammas RL, Movahed A. Sarcoidosis of the heart. Clin Cardiol 1993; 16: 462-472.
107. Ishikawa T, Kondoh H, Nakagawa S, Koiwaya Y, Tanaka K. Steroid therapy in cardiac sarcoidosis. Increased left ventricular contractility concomitant with electrocardiographic improvement after prednisolone. Chest 1984; 85(3): 445-447.
108. Yazaki Y, Isobe M, Hiramitsu S, Morimoto S, Hiroe M, Omichi C, Nakano T, Saeki M, Izumi T, Sekiguchi M. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol 1998; 82(4): 537-540.
109. Okayama K, Kurata C, Tawarahara K, Wakabayashi Y, Chida K, Sato A. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest 1995; 107(2): 330-334.
110. Lorell B, Alderman EL, Mason JW. Cardiac sarcoidosis. Diagnosis with endomyocardial biopsy and treatment with corticosteroids. Am J Cardiol 1978; 42: 143-146.
111. Oni AA, Hershberger RE, Norman DJ, Ray J, Hovaguimian H, Cobanoglu AM, Hosenpud JD. Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids. J Heart Lung Transplant 1992; 11(2 Pt 1): 367-369.
112. Shammas RL, Movahed A. Successful treatment of myocardial sarcoidosis with steroids. Sarcoidosis 1994; 11(1): 37-39.
113. Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, Izumi T, Sekiguchi M. Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88(9): 1006-1010.
114. Tachibana T, Ohmori F, Ueda E. Clinical study on cardiac sarcoidosis. Ann N Y Acad Sci 1986; 465: 530-542.
115. Walsh M. Systemic sarcoidosis with refractory ventricular tachycardia and heart failure. Br Heart J 1978; 40: 931-933.
116. Le Guludec D, Menad F, Faraggi M, Weinmann P, Battesti JP, Valeyre D. Myocardial sarcoidosis. Clinical value of technetium-99m sestamibi tomoscintigraphy. Chest 1994; 106(6): 1675-1682.
117. Tawarahara K, Kurata C, Okayama K, Kobayashi A, Yamazaki N. Thallium-201 and gallium 67 single photon emission computed tomographic imaging in cardiac sarcoidosis. Am Heart J 1992; 124: 1383-1384.
118. Shimada T, Shimada K, Sakane T, Ochiai K, Tsukihashi H, Fukui M, Inoue S, Katoh H, Murakami Y, Ishibashi Y, Maruyama R. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001; 110(7): 520-527.
119. Winters SL, Cohen M, Greenberg S, Stein B, Curwin J, Pe E, Gomes JA. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol 1991; 18(4): 937-943.
120. Takada K, Ina Y, Yamamoto M, Satoh T, Morishita M. Prognosis after pacemaker implantation in cardiac sarcoidosis in Japan. Clinical evaluation of corticosteroid therapy. Sarcoidosis 1994; 11(2): 113-117.
121. Chapelon C, Ziza JM, Piette JC, Levy Y, Raguin G, Wechsler B, Bitker MO, Bletry O, Laplane D, Bousser MG, et al. Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore) 1990; 69(5): 261-276.
122. Delaney P. Neurologic manifestations in sarcoidosis: review of the literature, with a report of 23 cases. Ann Intern Med 1977; 87(3): 336-345.
123. Leeds NE, Zimmerman RD, Elkin CM, Nussbaum M, LeVan AM. Neurosarcoidosis of the brain and meninges. Semin Roentgenol 1985; 20(4): 387-392.
124. Oksanen V. Neurosarcoidosis. Semin Resp Med 1992; 13: 459-467.
125. Sharma OP, Sharma AM. Sarcoidosis of the nervous system. Arch Intern Med 1991; 151: 1317-1321.
126. Teirstein AS. Neuromuscular sarcoidosis. Semin Resp Crit Care Med 2002; 23: 505-512.
127. Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997; 157(16): 1864-1868.
128. Brooks J, Strickland MC, Williams JP, Vulpe M, Fowler HL. Computed tomography changes in neurosarcoidosis clearing with steroid treatment. J Comp Assist Tomogr 1979; 3(3): 398-399.
129. Lexa FJ, Grossman RI. MR of sarcoidosis in the head and spine: spectrum of manifestations and radiographic response to steroid therapy. Am J Neuroradiol 1994; 15(5): 973-982.
130. Christoforidis GA, Spickler EM, Recio MV, Mehta BM. MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment. Am J Neuroradiol 1999; 20(4): 655-669.
131. Allen RK, Sellars RE, Sandstrom PA. A prospective study of 32 patients with neurosarcoidosis. Sarcoidosis Vasc Diff Lung Dis 2003; 20(2): 118-125.
132. Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995; 52(9): 875-879.
133. Stern BJ, Schonfeld SA, Sewell C, Krumholz A, Scott P, Belendiuk G. The treatment of neurosarcoidosis with cyclosporine. Arch Neurol 1992; 49(10): 1065-1072.
134. Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 2003; 124(5): 2023-2026.
135. Maddrey WC, Johns CJ, Boitnott JK, Iber FL. Sarcoidosis and chronic hepatic disease: a clinical and pathologic study of 20 patients. Medicine (Baltimore) 1970; 49(5): 375-395.
136. Valla D, Pessegueiro-Miranda H, Degott C. Hepatic sarcoidosis with portal hypertension: a report of seven cases. Q J Med 1987; 63: 531-544.
137. Devaney K, Goodman ZD, Epstein MS, Zimmerman HJ, Ishak KG. Hepatic sarcoidosis. Clinicopathologic features in 100 patients. Am J Surg Pathol 1993; 17(12): 1272-1280.
138. Hughes GS, Kataria YP, O’Brien TF. Sarcoidosis presenting as biliary cirrhosis: Treatment with chlorambucil. South Med J 1983; 76: 1440-1442.
139. Melissant CF, Smith SJ, Kazzaz BA, Demedts M. Bleeding varices due to portal hypertension in sarcoidosis. Favorable effect of propranolol and prednisone. Chest 1993; 103: 628-629.
140. Gerard AG, Roth AL, Becker SM, Shih CS. Regression of sarcoid hepatosplenomegaly on corticosteroid therapy. J Med Soc N J 1968; 65(2): 64-67.
141. Kataria YP, Whitcomb ME. Splenomegaly in sarcoidosis. Arch Intern Med 1980; 140: 35-37.
142. James DG. Sarcoidosis of the skin. Semin Resp Med 1992; 13: 432-441.
143. Sharma OP. Cutaneous sarcoidosis: clinical features and management. Chest 1972; 61(4): 320-325.
144. Zax RH, Callen JP. Sarcoidosis. Dermatol Clin 1989; 7: 505-515.
145. Zic JA, Horowitz DH, Arzubiaga C, King LE Jr. Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol 1991; 127(7): 1034-1040.
146. Mayock RL, Bertrand P, Morrison CE, Scott JH. Manifestations of sarcoidosis: analysis of 145 patients, with a review of nine series selected from the literature. Am J Med 1963; 35: 67-89.
147. Thomas P, Hunninghake G. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis 1987; 135: 747-760.
148. Lower EE, Smith JT, Martelo OJ, Baughman RP. The anemia of sarcoidosis. Sarcoidosis 1988; 5(1): 51-55.
149. Gupta D, Rao VM, Aggarwal AN, Garewal G, Jindal SK. Haematological abnormalities in patients of sarcoidosis. Indian J Chest Dis Allied Sci 2002; 44(4): 233-236.
150. Kennedy DW, Yamakido M. Hematologic manifestations of sarcoidosis. Semin Resp Med 1992; 13: 455-458.
151. Neville E, Carstairs LS, James DG. Sarcoidosis of bone. Q J Med 1977; 46: 215-277.
152. Dinerstein SL, Kovarsky J. Vertebral sarcoidosis: demonstration of bone involvement by computerized axial tomography. South Med J 1984; 77: 1060-1061.
153. Rohatgi PK. Osseous sarcoidosis. Semin Resp Med 1992; 13: 468-488.
154. Sartoris DJ, Resnick D, Resnik C, Yaghmai I. Musculoskeletal manifestations of sarcoidosis. Semin Roentgenol 1985; 20(4): 376-386.
155. Rizzato G, Tosi G, Schiraldi G, Montemurro L, Zanni D, Sisti S. Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis. Sarcoidosis 1988; 5(2): 99-103.
156. Montemurro L, Fraioli P, Riboldi A, Delpiano S, Zanni D, Rizzato G. Bone loss in prednisone treated sarcoidosis: a two-year follow-up. Ann Ital Med Int 1990; 5(3 Pt 1): 164-168.
157. Rizzato G, Riboldi A, Imbimbo B, Torresin A, Milani S. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis. Respir Med 1997; 91(8): 449-460.
158. Romer FK. Renal manifestations and abnormal calcium metabolism in sarcoidosis. Q J Med 1980; 49: 233-247.
159. Goldstein RA, Israel HL, Becker KL, Moore CF. The infrequency of hypercalcemia in sarcoidosis. Am J Med 1971; 51(1): 21-30.
160. Akmal M, Sharma OP. Renal sarcoidosis: a reminder. Chest 1990; 97: 1284-1285.
161. Muther RS, McCarron DA, Bennett WM. Renal manifestations of sarcoidosis. Arch Intern Med 1981; 141: 643-645.
162. Hoffbrand BI. The kidney in sarcoidosis. In: James DG, ed. Sarcoidosis and Other Granulomatous Disorders. New York: Marcel Dekker, 1994: 335-343.
163. Adams JS. Hypercalcemia and hypercalciuria. Semin Resp Med 1992; 13: 402-410.
164. Korzets Z, Schneider M, Taragan R, Bernheim J, Bernheim J. Acute renal failure due to sarcoid granulomatous infiltration of the renal parenchyma. Am J Kidney Dis 1985; 6(4): 250-253.
165. Zisman DA, Shorr A, Lynch JP III. Sarcoidosis involving the musculoskeletal system. Semin Resp Crit Care Med 2002; 23: 555-570.
166. Ando DG, Lynch JP III, Fantone JC III. Sarcoid myopathy with elevated creatine phosphokinase. Am Rev Respir Dis 1985; 131(2): 298-300.
167. Ost D, Yeldandi A, Cugell D. Acute sarcoid myositis with respiratory muscle involvement. Case report and review of the literature. Chest 1995; 107(3): 879-882.
168. Zisman DA, Biermann JS, Martinez FJ, Devaney KO, Lynch JP III. Sarcoidosis presenting as a tumorlike muscular lesion. Case report and review of the literature. Medicine (Baltimore) 1999; 78(2): 112-122.